Company Update
- CDSCO approval for 18.8% bed capacity expansion (138 to 164 beds) at Hyderabad BA/BE facility
- Zero Form 483 USFDA inspection outcome achieved on July 24, 2026
- Strong H2 FY26 operational turnaround with positive net margins
- Immediate operational readiness of expanded beds at existing facility
- Promoter shareholding reduced from 38.05% to 30.25% in Q4 FY26
- Low trailing ROCE of 5.0% and historic quarterly loss volatility
- Dependence on generic drug filings and CRO outsourcing budgets of pharma clients
- Promoter stake dropped from 38.05% in Dec 2025 to 30.25% in Mar 2026 (below 35% threshold)
Executive Summary & Catalyst Evaluation
On August 1, 2026, Jeevan Scientific received CDSCO approval to expand bed capacity from 138 to 164 beds (+18.8%) at its Hyderabad Bioavailability/Bioequivalence (BA/BE) center. This regulatory clearance directly follows a successful zero-483 USFDA inspection on July 24, 2026, establishing compliance credibility.
Financial Uplift Math
TTM Revenue stands at Rs 61.5 Cr. An 18.8% bed expansion provides physical capacity for ~Rs 11.5 Cr in additional annual revenue. Assuming a realistic 60% capacity utilization ramp in Year 1, Year 1 revenue uplift is estimated at 12% (~Rs 7.4 Cr), achieving steady-state 18.8% uplift (~Rs 11.5 Cr) in Year 2. With H2 FY26 demonstrating margin recovery (OPM ~20-22%), operating leverage on incremental beds is expected to generate ~35% steady-state EPS uplift over FY26 base EPS of Rs 0.58.
Governance & Mandate Caps
Promoter shareholding fell sharply from 38.05% in Dec 2025 to 30.25% in Mar 2026. Under strict research guardrails, a promoter holding below 35% automatically caps the multibagger verdict at POSSIBLE and confidence at <= 0.50.
Scenario Calibration
Base Case (+35% upside over 12-24m) assumes steady bed utilization ramp and annualized PAT of Rs 8-9 Cr. Bull Case (+75% upside) reflects full bed utilization and P/E re-rating following USFDA validation. Bear Case (-30% downside) accounts for potential further promoter selling or delayed study sign-ups.
